title: Severe acute motor neuropathy after treatment with triple tyrosine kinase inhibitor BIBF 1120 (Nintedanib).
authors: Department of Neurology, University of Rostock, Rostock, Germany. robert.patejdl@uni-rostock.de
authors: R
authors: R
authors: Patejdl
authors: S
authors: S
authors: Markmann
authors: R
authors: R
authors: Benecke
authors: M
authors: M
authors: Wittstock
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001369:Axons / Q000473:pathology; D003536:Cystadenocarcinoma / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D004568:Electrodiagnosis; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D016472:Motor Neuron Disease / Q000139:chemically induced* / Q000503:physiopathology; D009431:Neural Conduction / Q000502:physiology; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D010534:Peritoneal Neoplasms / Q000556:secondary; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D007211:Indoles; D011505:Protein-Tyrosine Kinases; C530716:nintedanib
keywords: Angiogenic agents; BIBF 1120; Chemotherapy-induced peripheral neuropathy; Ovarian cancer; Tyrosine kinase inhibitors